Molecular Mechanisms and Therapeutics for Spinocerebellar Ataxia Type 2

Polina A. Egorova, Ilya Bezprozvanny

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The effective therapeutic treatment and the disease-modifying therapy for spinocerebellar ataxia type 2 (SCA2) (a progressive hereditary disease caused by an expansion of polyglutamine in the ataxin-2 protein) is not available yet. At present, only symptomatic treatment and methods of palliative care are prescribed to the patients. Many attempts were made to study the physiological, molecular, and biochemical changes in SCA2 patients and in a variety of the model systems to find new therapeutic targets for SCA2 treatment. A better understanding of the uncovered molecular mechanisms of the disease allowed the scientific community to develop strategies of potential therapy and helped to create some promising therapeutic approaches for SCA2 treatment. Recent progress in this field will be discussed in this review article.

Original languageEnglish (US)
JournalNeurotherapeutics
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Spinocerebellar Ataxias
Therapeutics
Inborn Genetic Diseases
Palliative Care

Keywords

  • aggregation
  • calcium signaling
  • cerebellum
  • polyglutamine disorders
  • Spinocerebellar ataxia type 2

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Molecular Mechanisms and Therapeutics for Spinocerebellar Ataxia Type 2. / Egorova, Polina A.; Bezprozvanny, Ilya.

In: Neurotherapeutics, 01.01.2019.

Research output: Contribution to journalReview article

@article{55981bbfa1af44d793b194503cad6186,
title = "Molecular Mechanisms and Therapeutics for Spinocerebellar Ataxia Type 2",
abstract = "The effective therapeutic treatment and the disease-modifying therapy for spinocerebellar ataxia type 2 (SCA2) (a progressive hereditary disease caused by an expansion of polyglutamine in the ataxin-2 protein) is not available yet. At present, only symptomatic treatment and methods of palliative care are prescribed to the patients. Many attempts were made to study the physiological, molecular, and biochemical changes in SCA2 patients and in a variety of the model systems to find new therapeutic targets for SCA2 treatment. A better understanding of the uncovered molecular mechanisms of the disease allowed the scientific community to develop strategies of potential therapy and helped to create some promising therapeutic approaches for SCA2 treatment. Recent progress in this field will be discussed in this review article.",
keywords = "aggregation, calcium signaling, cerebellum, polyglutamine disorders, Spinocerebellar ataxia type 2",
author = "Egorova, {Polina A.} and Ilya Bezprozvanny",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s13311-019-00777-6",
language = "English (US)",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",

}

TY - JOUR

T1 - Molecular Mechanisms and Therapeutics for Spinocerebellar Ataxia Type 2

AU - Egorova, Polina A.

AU - Bezprozvanny, Ilya

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The effective therapeutic treatment and the disease-modifying therapy for spinocerebellar ataxia type 2 (SCA2) (a progressive hereditary disease caused by an expansion of polyglutamine in the ataxin-2 protein) is not available yet. At present, only symptomatic treatment and methods of palliative care are prescribed to the patients. Many attempts were made to study the physiological, molecular, and biochemical changes in SCA2 patients and in a variety of the model systems to find new therapeutic targets for SCA2 treatment. A better understanding of the uncovered molecular mechanisms of the disease allowed the scientific community to develop strategies of potential therapy and helped to create some promising therapeutic approaches for SCA2 treatment. Recent progress in this field will be discussed in this review article.

AB - The effective therapeutic treatment and the disease-modifying therapy for spinocerebellar ataxia type 2 (SCA2) (a progressive hereditary disease caused by an expansion of polyglutamine in the ataxin-2 protein) is not available yet. At present, only symptomatic treatment and methods of palliative care are prescribed to the patients. Many attempts were made to study the physiological, molecular, and biochemical changes in SCA2 patients and in a variety of the model systems to find new therapeutic targets for SCA2 treatment. A better understanding of the uncovered molecular mechanisms of the disease allowed the scientific community to develop strategies of potential therapy and helped to create some promising therapeutic approaches for SCA2 treatment. Recent progress in this field will be discussed in this review article.

KW - aggregation

KW - calcium signaling

KW - cerebellum

KW - polyglutamine disorders

KW - Spinocerebellar ataxia type 2

UR - http://www.scopus.com/inward/record.url?scp=85071301947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071301947&partnerID=8YFLogxK

U2 - 10.1007/s13311-019-00777-6

DO - 10.1007/s13311-019-00777-6

M3 - Review article

C2 - 31435879

AN - SCOPUS:85071301947

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

ER -